自贡地区原发性支气管肺癌中医证型分布规律研究
Distribution of Traditional Chinese Medicine Syndrome Types of Primary Bronchogenic Lung Cancer in Zigong Area
DOI: 10.12677/tcm.2026.1510599, PDF,    科研立项经费支持
作者: 罗飞燕, 张巨江, 邱 凤, 黄建清*:自贡市中医医院(成都中医药大学附属自贡医院)肿瘤血液科,四川 自贡
关键词: 原发性支气管肺癌;中医证型;证素;辨证分型;分布规律;自贡地区;Primary Bronchogenic Lung Cancer; TCM Syndrome Type; Syndrome Element; Syndrome Differentiation and Classification; Distribution Patterns; Zigong Area
摘要: 目的:探讨自贡市中医医院就诊的原发性支气管肺癌患者的中医证型分布规律,为肺癌中医辨证规范化及个体化诊疗提供客观依据。方法:采用前瞻性研究方法,纳入2020年12月~2023年10月自贡市中医医院门诊及住院的原发性支气管肺癌患者410例,采集一般资料、肿瘤情况与四诊信息,依据八纲、气血及脏腑辨证原则,以“先辨单证、单证相合构成复证”的方法进行辨证分型,并分析证型与病理类型、临床分期的相关性。结果:410例患者中,男女比例约1:1;年龄26~89岁,平均(60.0 ± 10.9)岁,以40~70岁为高发。病理类型以腺癌(297例,72.4%)最多,其次为鳞癌(73例,17.8%);临床分期以III、IV期为主(266例,64.9%)。病性证素以气虚(220例,53.7%)居首,其后依次为痰湿(122例,29.8%)、血瘀(86例,21.0%)、痰热(73例,17.8%)、阴虚(45例,11.0%)、气滞(14例,3.4%)。单一证候以气虚证、痰湿证为主;复合证候以气虚痰湿、气虚阴虚、气虚血瘀最为多见。病位以肺为核心(410例,100%),兼及脾(139例,33.9%)、肾(82例,20.0%)为主。结论:自贡市中医医院就诊的原发性支气管肺癌患者以“正气亏虚为本,痰、瘀、热、毒为标”,病位主要在肺,与脾、肾密切相关;证型呈本虚标实、虚实夹杂之特点。确立以气虚为主、兼夹痰瘀的证候格局,对肺癌中医辨证分型标准化及中西医结合全程管理具有参考意义。
Abstract: Objective: To investigate the distribution of traditional Chinese medicine (TCM) syndrome types among patients with primary bronchogenic lung cancer admitted to Zigong Hospital of Traditional Chinese Medicine, so as to provide objective evidence for the standardization of TCM syndrome differentiation and individualized diagnosis and treatment of lung cancer. Methods: A prospective study was conducted. A total of 410 patients with primary bronchogenic lung cancer admitted to the outpatient and inpatient departments of Zigong Hospital of Traditional Chinese Medicine from December 2020 to October 2023 were enrolled. General data, tumor characteristics and four-diagnosis information were collected. Syndrome differentiation was performed based on the principles of eight-principle, qi-blood and zang-fu differentiation, using the method of “first identifying single syndromes and then combining them to form compound syndromes”, followed by analysis of the correlations of syndrome types with pathological type and clinical stage. Results: The male-to-female ratio was about 1:1, and the age ranged from 26 to 89 years, with a mean of (60.0 ± 10.9) years, with a high incidence in the 40~70-year age group. Adenocarcinoma was the most common pathological type (297 cases, 72.4%), followed by squamous cell carcinoma (73 cases, 17.8%). Stage III and IV accounted for the majority (266 cases, 64.9%). Among disease-nature syndrome elements, qi deficiency ranked first (220 cases, 53.7%), followed by phlegm-dampness (122 cases, 29.8%), blood stasis (86 cases, 21.0%), phlegm-heat (73 cases, 17.8%), yin deficiency (45 cases, 11.0%) and qi stagnation (14 cases, 3.4%), with single syndromes dominated by qi deficiency and phlegm-dampness and compound syndromes most commonly comprising qi deficiency with phlegm-dampness, qi deficiency with yin deficiency, and qi deficiency with blood stasis. The lung was the core disease location (410 cases, 100%), with the spleen (139 cases, 33.9%) and kidney (82 cases, 20.0%) as the main additional disease locations. Conclusion: Among patients with primary bronchogenic lung cancer admitted to Zigong Hospital of Traditional Chinese Medicine, the disease is characterized by “deficiency of vital qi as the root, and phlegm, blood stasis, heat and toxin as the branch”, with the disease mainly located in the lung and closely related to the spleen and kidney, showing a syndrome pattern of deficiency in root and excess in branch, and a mixture of deficiency and excess. Establishing the syndrome pattern dominated by qi deficiency complicated with phlegm and blood stasis is instructive for the standardization of TCM syndrome differentiation and the whole-course integrative management of lung cancer.
文章引用:罗飞燕, 张巨江, 邱凤, 黄建清. 自贡地区原发性支气管肺癌中医证型分布规律研究[J]. 中医学, 2026, 15(10): 635-643. https://doi.org/10.12677/tcm.2026.1510599

参考文献

[1] Sung, H., Filho, A.M., Laversanne, M., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2026) Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries. CA: A Cancer Journal for Clinicians, 76, e70090.
https://doi.org/10.3322/caac.70090
[2] 刘悦, 滕熠, 郑渊杰, 等. GLOBOCAN 2024全球癌症统计数据解读[J].中国肿瘤, 2026, 35(9): 661-669.
[3] 郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
[4] 董婷, 成姝雯, 胥馨尹, 等. 2009-2017年四川省肿瘤登记地区肺癌发病和死亡流行特征分析[J]. 中国肿瘤, 2022, 31(6): 437-441.
[5] 林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 294-295.
[6] 司富春, 宋雪杰, 陈瑞, 等. 原发性支气管肺癌中医证候和方药分布规律文献研究[J]. 中医杂志, 2014, 55(13): 1146-1151.
[7] 游捷, 李泰峰, 汪霞, 等. 303例老年原发性支气管肺癌中医证候分型[J]. 中医杂志, 2012, 53(16): 1404-1407.
[8] 郁仁存. 中医肿瘤学[M]. 北京: 科学出版社, 1983.
[9] 杜秀婷, 刘鹏, 刘柏, 等. 原发性支气管肺癌中医证型与病理类型的相关性研究[J]. 中医药导报, 2019, 25(24): 18-21, 25.
[10] 王保芹, 华文山, 杨敏. 近20年肺癌中医辨证分型研究[J]. 中医药导报, 2024, 30(10): 90-94.
[11] 非小细胞肺癌常见证候分布规律的多中心、横断面临床研究[J]. 中华中医药杂志, 2026, 41(8): 2334-2341.
[12] 杨丽廷, 倪雪莉. 晚期非小细胞肺癌中医证型与PD-L1表达的相关性及免疫治疗后的演变[J]. 实用中医内科杂志, 2026, 40(6): 63-67.
[13] 马军燕, 吴琼, 董量, 等. 中医证素参与的晚期非小细胞肺癌PD-1抑制剂近期疗效预测模型构建与验证[J]. 肿瘤防治研究, 2023, 50(10): 960-967.
[14] 原发性肺癌诊疗规范(2018年版) [J]. 肿瘤综合治疗电子杂志, 2019, 5(3): 100-120.
[15] Lim, W., Ridge, C.A., Nicholson, A.G. and Mirsadraee, S. (2018) The 8th Lung Cancer TNM Classification and Clinical Staging System: Review of the Changes and Clinical Implications. Quantitative Imaging in Medicine and Surgery, 8, 709-718.
https://doi.org/10.21037/qims.2018.08.02